GLP-1

Tirzepatide vs. Semaglutide: The Definitive 2026 Head-to-Head Comparison

Medici

29 Apr 2026 — 5 min read

Two injectable medications are reshaping obesity medicine: tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy). Both belong to the GLP-1 drug class, both are once-weekly injections, and both produce clinically meaningful weight loss. But the similarities mostly end there.

In May 2025, the landmark SURMOUNT-5 trial published in the New England Journal of Medicine delivered the first rigorous head-to-head comparison. The results were decisive: tirzepatide produced 47% greater weight loss than semaglutide over 72 weeks. But weight loss percentages don't tell the whole story. This guide breaks down everything you need to know — mechanisms, clinical data, side effects, dosing, cost, and which drug is right for you.

Mechanism of Action: GLP-1 vs. Dual GIP/GLP-1

The core difference between these two drugs is what they target at the receptor level.

Semaglutide: Pure GLP-1 Receptor Agonist

Semaglutide mimics glucagon-like peptide-1 (GLP-1), a gut hormone naturally released after eating. By binding to GLP-1 receptors throughout the body, semaglutide:

Slows gastric emptying (food moves through your stomach more slowly)
Suppresses appetite by acting on hypothalamic satiety centers in the brain
Stimulates insulin release in a glucose-dependent manner
Reduces glucagon secretion, lowering liver glucose output

The net result: you eat less, feel full longer, and your blood sugar stabilizes. Semaglutide (as Ozempic) was originally FDA-approved for type 2 diabetes in 2017; the higher-dose Wegovy formulation received obesity approval in 2021.

Tirzepatide: Dual GIP/GLP-1 Receptor Agonist

Tirzepatide takes a fundamentally different approach. It is a single synthetic molecule that acts simultaneously on two receptors:

GLP-1 receptors — same targets as semaglutide
GIP receptors (glucose-dependent insulinotropic polypeptide) — a second gut hormone that enhances insulin secretion, reduces appetite, and appears to improve fat metabolism in adipose tissue

This dual mechanism is not simply additive — GIP appears to potentiate GLP-1's effects, particularly on satiety and fat burning. Research published in Nature Metabolism suggests GIP receptor activation may reduce the nausea associated with GLP-1 agonism, which could explain why tirzepatide users tend to tolerate higher doses.

Head-to-Head Clinical Evidence

SURMOUNT-5: The Definitive Trial

Published May 2025 in the New England Journal of Medicine, SURMOUNT-5 enrolled 751 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity — but without type 2 diabetes. Participants were randomized 1:1 to:

Tirzepatide at maximum tolerated dose (10 mg or 15 mg weekly)
Semaglutide at maximum tolerated dose (1.7 mg or 2.4 mg weekly)

After 72 weeks:

Mean body weight reduction: −20.2% (tirzepatide) vs. −13.7% (semaglutide)
Average weight lost (absolute): 22.9 kg / 50.4 lbs (tirzepatide) vs. 15.0 kg / 33.1 lbs (semaglutide)
Waist circumference reduction: −18.4 cm / 7.2 in (tirzepatide) vs. −13.0 cm / 5.1 in (semaglutide)
Relative difference: Tirzepatide produced approximately 47% greater weight loss

A post-hoc analysis published in European Heart Journal Open found tirzepatide was also associated with a significantly greater predicted reduction in 10-year cardiovascular disease risk.

SURPASS-2: Diabetes Population

In people with type 2 diabetes, SURPASS-2 directly compared tirzepatide (5 mg, 10 mg, 15 mg) vs. semaglutide 1 mg weekly. Tirzepatide outperformed across all three doses on both HbA1c reduction (−2.0% to −2.3% vs. −1.86%) and weight loss.

Meta-Analysis Support

A 2025 systematic review and meta-analysis confirmed: tirzepatide produces significantly greater weight loss than semaglutide (mean difference: 4.23%, 95% CI: 3.22–5.25%, p < 0.01).

Side Effect Profiles

Both drugs share the same fundamental GI side effect profile — this is a class effect of gut hormone agonism. The most common adverse events for both include nausea (most common, especially during dose escalation), vomiting, diarrhea, constipation, abdominal discomfort, and reduced appetite.

GI side effects occur in over 50% of users on either drug and are typically most pronounced during the first few months. They generally diminish over time.

Tolerability Differences

Several analyses suggest tirzepatide may have a slightly more favorable tolerability profile despite achieving greater weight loss. The leading hypothesis: GIP receptor activation dampens some of the nausea driven by GLP-1 agonism. That said, at the highest doses of tirzepatide (15 mg), GI side effects can be significant.

Rare but serious risks (both drugs):

Pancreatitis — rare; discontinue if suspected
Gallbladder disease (cholelithiasis)
Thyroid C-cell tumors — black box warning; avoid in personal/family history of medullary thyroid carcinoma or MEN 2
Gastroparesis with chronic use
Hypoglycemia — mainly when combined with insulin or sulfonylureas

Dosing Protocols

Semaglutide (Wegovy — weight loss formulation)

Semaglutide uses a structured 17-week escalation:

Weeks 1–4: 0.25 mg once weekly
Weeks 5–8: 0.5 mg once weekly
Weeks 9–12: 1.0 mg once weekly
Weeks 13–16: 1.7 mg once weekly
Week 17+: 2.4 mg once weekly (maintenance)

Tirzepatide (Zepbound — weight loss formulation)

Tirzepatide uses a longer, 21-week escalation to 15 mg:

Weeks 1–4: 2.5 mg once weekly
Weeks 5–8: 5 mg once weekly
Weeks 9–12: 7.5 mg once weekly
Weeks 13–16: 10 mg once weekly
Weeks 17–20: 12.5 mg once weekly
Week 21+: 15 mg once weekly (maximum dose)

Both are subcutaneous injections in the abdomen, thigh, or upper arm, rotating sites weekly.

Blood Sugar Control for Type 2 Diabetes

Both medications provide meaningful glycemic control, but tirzepatide leads:

Tirzepatide: HbA1c reductions of 2.0%–2.4% from baseline
Semaglutide: HbA1c reductions of 1.5%–1.8% from baseline

For people with type 2 diabetes who need both weight management and glycemic control, tirzepatide (Mounjaro) offers a compelling dual advantage.

Cardiovascular Benefits

Both drugs carry cardiovascular data, but with an important asymmetry:

Semaglutide has the longer and more comprehensive track record. The SELECT trial (2023) showed a 20% reduction in major adverse cardiovascular events in patients with obesity and established cardiovascular disease — without diabetes.
Tirzepatide shows promising cardiovascular signals. The SURMOUNT-5 post-hoc analysis found greater predicted 10-year CVD risk reduction vs. semaglutide. A Cleveland Clinic real-world study found tirzepatide associated with significantly lower risks of MACE and all-cause mortality in patients with metabolic liver disease. The definitive tirzepatide cardiovascular outcomes trial (SURPASS-CVOT) is still ongoing.

Cost and Access in 2026

Brand-Name Pricing

Zepbound/Mounjaro (tirzepatide): $1,400–$1,600/month retail
Wegovy/Ozempic (semaglutide): $1,300–$1,900/month retail

Manufacturer Savings

Eli Lilly's LillyDirect Self-Pay Journey: tirzepatide for $299–$449/month for uninsured patients
Novo Nordisk's NovoCare program offers similar savings for semaglutide

Insurance in 2026

Coverage for weight-loss indications (Zepbound, Wegovy) is inconsistent and increasingly restricted. Many employer plans removed anti-obesity coverage in 2025–2026. Medicare covers the diabetes formulations (Mounjaro, Ozempic) under Part D for type 2 diabetes only.

Compounded GLP-1s

Following FDA shortage designations, compounding pharmacies produced copies at dramatically lower cost. As of 2025:

The FDA ended 503B outsourcing facility compounding for tirzepatide in March 2025 and semaglutide in April 2025
State-licensed 503A pharmacies remain a compliant path for individualized prescriptions: typically $199–$400/month
Compounded saves 77–84% vs. brand retail

Always verify pharmacy accreditation (PCAB or state board approval) and require a valid prescription.

Which Drug Is Right for You?

Choose Tirzepatide (Zepbound/Mounjaro) if:

Maximum weight loss is your primary goal
You have type 2 diabetes and want superior glycemic control alongside weight loss
You've tried semaglutide with inadequate results
You have access to Lilly's savings programs or favorable coverage

Choose Semaglutide (Wegovy/Ozempic) if:

You have established cardiovascular disease and want the drug with the most robust outcomes data (SELECT trial)
Your insurance covers semaglutide but not tirzepatide
You prefer an oral option (Rybelsus — oral semaglutide; no oral tirzepatide equivalent exists yet)
You've responded well to semaglutide previously

The Bottom Line

The SURMOUNT-5 trial settled the efficacy debate: tirzepatide produces approximately 47% more weight loss than semaglutide in people with obesity. Its dual GIP/GLP-1 mechanism confers additive benefits on satiety, fat metabolism, and glycemic control that a pure GLP-1 agonist cannot fully replicate.

That said, semaglutide is not obsolete. It carries a longer clinical track record, more robust cardiovascular outcomes data, an oral formulation, and broader insurance coverage. For patients with established ASCVD or those who respond well to semaglutide therapy, it remains the appropriate choice.

The best medication is always the one your prescriber recommends based on your complete clinical picture: your weight loss goals, metabolic risk factors, cardiovascular history, cost constraints, and tolerability. Always consult a qualified healthcare provider before starting either drug.

This article is for educational purposes only and does not constitute medical advice.